Oral formulations of Glycyl-2-Methylprolyl-Glutamate.
Author: Wen, Jingyuan; Thomas, G; Bickerdike, MJ
Link to this item using this URL: http://hdl.handle.net/2292/16990
Oral formulations of G-2MePE including microemulsions, coarse emulsions, liquid crystals, tablets and encapsulated forms of G-2MePE have improved bioavailability than conventional aqueous formulations. In particular, microparticles, nanoparticles and microemulsions can exhibit great neuroprotective effects after oral administration. In a microemulsion formulation, G-2MePE can nearly completely inhibit cerebral infarction in an animal model of stroke even after the stroke had been initiated. Thus, improved oral formulations can be desirably used to treat a variety of neurodegenerative conditions with improved convenience and improved efficacy.
Citation: ["Patent/Trademark number: US 2009/0074865 A1 (United States). Application number: 12/283,684. Filed date: 15 Sep 2008. Application date: 19 Mar 2009. Awarded date: 19 Mar 2009"]